Antithrombotic therapy & VTE
Anticoagulation, triple therapy and venous thromboembolism.
- Trials
- 11
- Years
- 2012–2026
Sort
- 2026OCEANIC-STROKE CoreIn 12,327 patients with non-cardioembolic stroke or high-risk TIA, asundexian reduced recurrent ischemic stroke compared with placebo.HR 0.7495% CI 0.65-0.84Read →
- 2024ANNEXA-Ifactor Xa reversalIn 530 patients with factor Xa inhibitor-associated intracerebral haemorrhage, andexanet alfa improved haemostatic efficacy compared with usual care.67.0% vs 53.1%Read →
- 2020CARAVAGGIOVenous thromboembolismIn 1,170 patients with cancer-associated venous thromboembolism, apixaban was non-inferior to dalteparin for recurrent VTE, without excess major bleeding.HR 0.63Read →
- 2019AUGUSTUS CoreAF + PCIIn 4,614 patients with AF and recent ACS or PCI, apixaban without aspirin reduced major or clinically relevant bleeding compared with warfarin-based triple therapy.Read →
- 2017COMPASSChronic atherosclerosisIn 27,395 patients with stable coronary or peripheral artery disease, low-dose rivaroxaban plus aspirin reduced cardiovascular death, stroke or MI compared with aspirin alone.HR 0.76Read →
- 2014PEITHO CorePulmonary embolismIn 1,006 patients with intermediate-risk pulmonary embolism, tenecteplase reduced haemodynamic decompensation but increased major and intracranial bleeding compared with heparin alone.OR 0.44Read →
- 2014ULTIMAPulmonary embolismIn 59 patients with intermediate-risk pulmonary embolism and right-ventricular dilatation, ultrasound-assisted catheter-directed thrombolysis reversed the right-ventricular-to-left-ventricular diameter ratio at 24 hours more than unfractionated heparin alone.Read →
- 2013WOESTAF + PCIIn 573 patients on oral anticoagulation undergoing PCI, clopidogrel without aspirin reduced bleeding compared with triple therapy.HR 0.36Read →
- 2013AMPLIFY CoreVenous thromboembolismIn 5,395 patients with acute venous thromboembolism, apixaban was non-inferior to conventional heparin–warfarin therapy for recurrent VTE, with far less major bleeding.2.3% vs 2.7%Read →
- 2013HOKUSAI-VTEVenous thromboembolismIn 8,240 patients with acute venous thromboembolism after initial heparin, once-daily edoxaban was non-inferior for recurrent symptomatic venous thromboembolism and caused less clinically relevant bleeding than warfarin.HR 0.8995% CI 0.70-1.13Read →
- 2012EINSTEIN-PEPulmonary embolismIn 4,832 patients with acute symptomatic pulmonary embolism, single-drug oral rivaroxaban was non-inferior for recurrent venous thromboembolism and halved major bleeding compared with enoxaparin followed by a vitamin K antagonist.HR 1.1295% CI 0.75-1.68Read →